Judith Aberg
Infectious Disease
Credentials: · · · ·
History
- 1990–1993
Internal Medicine
- 1986–1990
Research
An inflammatory cytokine signature predicts COVID-19 severity and survival
Nature Medicine · 2020 · 2,039 citations
Robust neutralizing antibodies to SARS-CoV-2 infection persist for months
Science · 2020 · 872 citations
JAMA · 2012 · 700 citations
70 papers
63 papers
- MZ
62 papers
60 papers
58 papers
57 papers · 2 as a fellow
45 papers · 31 as a resident
- ML
42 papers
Grants
- 2007–2014
New York University HIV/AIDS Clinical Trial Unit
National Institute of Allergy and Infectious Diseases · UM1
Contact PI · $2.9M · New York University School of Medicine
- 2007–2013
New York University HIV/AIDS Clinical Trial Unit
National Institute of Allergy and Infectious Diseases · U01
Contact PI · $7.5M · New York University School of Medicine
- 2009–2011
Virologic and Serologic Outcomes of Persons with HIV and HBV Co-Infection on Mono
National Institute of Allergy and Infectious Diseases · R21
Contact PI · $465K · New York University School of Medicine
- 2005–2009
General Clinical Research Center
National Center for Research Resources · M01
Project lead · $4.4M · New York University School of Medicine
Clinical trials
- 2012–2013
Pharmacokinetic Study of Pitavastatin and Ritonavir-Boosted Darunavir or Efavirenz
Principal investigator · Completed · Phase 1
NYU Langone Health
- 2006–2008
DB289 Versus TMP-SMX for the Treatment of Acute Pneumocystis Jiroveci Pneumonia (PCP)
Principal investigator · Terminated · Phase 3
Immtech Pharmaceuticals, Inc
- 2014–2015
Modulation of Immune Activation by Aspirin
Study chair · Completed · Phase 2
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- 2011–2014
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Study chair · Completed · Phase 2
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections